サンプル依頼リスト カート
  • English
  • Korean
表紙：神経栄養性角膜炎治療の世界市場レポート 2024年
市場調査レポート
商品コード
1415715

神経栄養性角膜炎治療の世界市場レポート 2024年

Neurotrophic Keratitis Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
神経栄養性角膜炎治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

神経栄養性角膜炎治療の市場規模は近年力強く成長しています。2023年の47億米ドルから2024年には51億米ドルへとCAGR8.5％で拡大します。実績期間の成長は、診断の増加、傷害と外科手術の増加、研究開発の上昇、世界医療インフラに起因します。

神経栄養性角膜炎治療市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR7.6％で68億2,000万米ドルに成長します。予測期間の成長は、教育イニシアティブ、臨床試験の増加、先進治療、規制当局の承認に起因すると考えられます。予測期間の主要動向には、診断ツールの改善、デジタルヘルスソリューション、神経保護戦略、高度な眼表面イメージングなどがあります。

眼疾患の罹患率の増加は、当面の神経栄養性角膜炎治療市場の拡大を牽引すると予測されます。眼疾患には、眼の構造や機能に影響を及ぼす医学的問題や障害が幅広く含まれます。神経栄養性角膜炎治療は、角膜の感覚を高め、治癒を促進し、感染を回避し、痛みや不快感を和らげる上で重要な役割を果たしています。例えば、米国を拠点とするアイケアキャリア開発サービスのプラットフォームであるアイケアワンが2022年3月に報告したところによると、米国では2022年に推定3,500万人がドライアイ（DED）を経験し、有病率は年々増加すると予測されています。さらに2021年3月、スペインに本部を置く非営利団体Eyes of the World Foundationのデータによると、2021年に視力低下を経験する人は11億人に上り、2050年には17億人に達すると予測されています。従って、眼疾患の発生率の高まりが神経栄養性角膜炎治療市場の成長に舵を切っています。

特に眼科領域における医療投資の急増は、当面の神経栄養性角膜炎治療市場拡大の原動力になると予測されています。このような投資は、医療サービスや治療法の開発、強化、利用可能性の強化に財源を振り向けるものであり、特に視力に関連する健康要件への対応に重点が置かれています。このような投資は、神経栄養性角膜炎治療の発展を促進する大きな可能性を秘めています。画期的な治療法や医薬品の開発に道を開き、最終的には患者の予後を改善し、この症状に悩む人々の生活の質を高めることにつながります。例えば、2023年3月、米国の著名な公衆衛生機関である疾病対策予防センター（CDC）は、議会に対する2023年度の予算要求が106億7,500万米ドルの包括的な資金パッケージであったと報告しました。この資金は、裁量予算、公衆衛生局（PHS）評価基金、予防・公衆衛生基金（PPHF）に配分されました。注目すべきは、CDCの2023年度大統領予算では特に1,000ドルが計上され、事業計画では2,500ドルが視力と目の健康イニシアチブに割り当てられたことです。この大幅な財政支出は、医療、特に眼科医療への投資の拡大を強調するものであり、神経栄養性角膜炎治療市場拡大の原動力となっています。

2023年の神経栄養性角膜炎治療市場で最大の地域は北米でした。神経栄養性角膜炎治療レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の神経栄養性角膜炎治療市場の促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の神経栄養性角膜炎治療の市場規模実績と成長、2018～2023年
  • 世界の神経栄養性角膜炎治療市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界の神経栄養性角膜炎治療市場、治療別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 局所抗生物質
  • 組換えヒト神経成長因子（rhNGF）
  • 羊膜移植
  • 角膜形成術
  • その他の治療
  • 世界の神経栄養性角膜炎治療市場、投与経路別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 経口
  • 局所
  • その他の投与経路
  • 世界の神経栄養性角膜炎治療市場、用途別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • ステージI
  • ステージII
  • ステージIII
  • 世界の神経栄養性角膜炎治療市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 病院
  • 在宅医療
  • 専門クリニック
  • その他のエンドユーザー

第7章 地域と国の分析

  • 世界の神経栄養性角膜炎治療市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
  • 世界の神経栄養性角膜炎治療市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 神経栄養性角膜炎治療市場の競合情勢
  • 神経栄養性角膜炎治療市場の企業プロファイル
    • Eyevance Pharmaceuticals LLC
    • Grand Pharma Co. Ltd.
    • Walgreen Co.
    • Pfizer Inc.
    • Johnson and Johnson

第31章 その他の主要と革新的な企業

  • Bayer AG
  • Novartis AG
  • Abbott Laboratories
  • Gilead Biosciences Inc.
  • Merck and Co. Inc.
  • Allergan Inc.
  • Alcon Inc.
  • Bausch Health Companies Inc.
  • Bausch & Lomb Inc.
  • CooperVision Inc.
  • Rohto Pharmaceutical Co. Ltd.
  • Santen Pharmaceutical Co. Ltd.
  • Zhejiang Conba Pharmaceutical Co. Ltd.
  • Glenmark Pharmaceuticals Limited
  • Dompe farmaceutici S.p.A

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

目次
Product Code: r12314

“Neurotrophic Keratitis Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurotrophic keratitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurotrophic keratitis treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The neurotrophic keratitis treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Treatment: Topical Antibiotics; Recombinant Human Nerve Growth Factor (rhNGF); Amniotic Membrane Transplantation; Keratoplasty; Other Treatments
  • 2) By Route of Administration: Oral; Topical; Other Routes of Administration
  • 3) By Application: Stage I; Stage II; Stage III
  • 4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
  • Companies Mentioned: Eyevance Pharmaceuticals LLC; Grand Pharma Co. Ltd.; Walgreen Co.; Pfizer Inc.; Johnson and Johnson
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Neurotrophic keratitis treatment is a method aimed at addressing a rare eye condition resulting from damage to the trigeminal nerve, leading to reduced corneal sensation and potential corneal harm. The objective of this treatment is to safeguard the cornea, facilitate recovery, alleviate symptoms, and prevent further damage. aimed at addressing a rare.

The main approaches of neurotrophic keratitis treatment are employed in neurotrophic keratitis treatment, including topical antibiotics, recombinant human nerve growth factor (rhNGF), amniotic membrane transplantation, keratoplasty, among others. Topical antibiotics are antimicrobial drugs administered directly to the skin or mucous membranes. They can be administered through various routes, such as oral, topical, and others, catering to stages I, II, and III of neurotropic keratitis. These treatments are utilized by different end-users, including hospitals, homecare, specialty clinics, among others.

The neurotrophic keratitis treatment market research report is one of a series of new reports from The Business Research Company that provides neurotrophic keratitis treatment market statistics, including neurotrophic keratitis treatment industry global market size, regional shares, competitors with a neurotrophic keratitis treatment market share, detailed neurotrophic keratitis treatment market segments, market trends and opportunities and any further data you may need to thrive in the neurotrophic keratitis treatment industry. This neurotrophic keratitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurotrophic keratitis treatment market size has grown strongly in recent years. It will grow from $4.7 billion in 2023 to $5.1 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increased diagnoses, increasing injury and surgical procedures, rising research and development, global healthcare infrastructure.

The neurotrophic keratitis treatment market size is expected to see strong growth in the next few years. It will grow to $6.82 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to educational initiatives, increasing clinical trials, advanced therapies, regulatory approvals. Major trends in the forecast period include improved diagnostic tools, digital health solutions, neuroprotection strategies, advanced ocular surface imaging.

The escalating incidence of eye conditions is anticipated to drive the expansion of the neurotrophic keratitis treatment market in the foreseeable future. Eye conditions encompass a wide spectrum of medical issues and disorders affecting the structure and functionality of the eyes. Neurotrophic keratitis treatment plays a crucial role in enhancing corneal sensation, fostering healing, averting infections, and alleviating pain and discomfort. For example, in March 2022, as reported by Eye Care One, a US-based platform for eyecare career development services, an estimated 35 million individuals in the United States were projected to experience dry eye disease (DED) in 2022, with prevalence expected to increase annually. Additionally, in March 2021, as per data from the Eyes of the World Foundation, a non-profit organization based in Spain, it was predicted that there would be 1.1 billion people experiencing vision loss in 2021, a number projected to rise to 1.7 billion by 2050. Hence, the mounting incidence of eye conditions is steering the growth of the neurotrophic keratitis treatment market.

The surge in healthcare investments, particularly in the domain of eye care, is anticipated to be a driving force behind the expansion of the neurotrophic keratitis treatment market in the foreseeable future. These investments involve directing financial resources towards bolstering the development, enhancement, and availability of medical services and treatments, with a special emphasis on addressing vision-related health requirements. Such investments hold significant potential in propelling the advancement of neurotrophic keratitis treatment. They have the capacity to pave the way for groundbreaking therapies and the development of pharmaceuticals, ultimately leading to improved outcomes for patients and an elevated quality of life for those grappling with this condition. For instance, in March 2023, the Centers for Disease Control and Prevention (CDC), a prominent U.S. national public health agency, reported that their budget request for FY 2023 to Congress encompassed a comprehensive funding package of $10.675 billion. This funding was allocated across discretionary budget authority, Public Health Service (PHS) Evaluation Funds, and the Prevention and Public Health Fund (PPHF). Notably, the CDC's FY 2023 President's Budget specifically earmarked $1,000, while the operating plan allotted $2,500 towards vision and eye health initiatives. This substantial financial commitment underscores the escalating investments in healthcare, particularly in the realm of eye care, and is a driving force behind the expansion of the neurotrophic keratitis treatment market.

Rising treatment expenses are anticipated to impede the neurotrophic keratitis treatment market in the future. The costs associated with treating neurotrophic keratitis (NK) have risen, largely attributed to the introduction of advanced therapies like Cenegermin (Oxervate), a medication containing recombinant human nerve growth factor (rhNGF). For instance, in March 2022, the National Center for Biotechnology Information (NCBI), a US-based organization specializing in biomedical research and information, reported that in Germany, the total cost of an eight-week course of Cenegermin 20 mg/ml therapy is approximately $21.20 USD (20.000 EURO). This is nearly 25 times pricier than a 16-week supply of autologous serum eye drops, six times more costly than amniotic membrane transplantation (AMT), and three times the expense of penetrating keratoplasty (PK) in Germany. As a result, the escalating treatment expenses are acting as a constraint on the neurotrophic keratitis treatment market.

Prominent companies in the neurotrophic keratitis treatment market are actively engaged in the development and approval of innovative drugs to fortify their market presence. Drug development holds significant importance in the treatment of neurotrophic keratitis, given the existing limitations in available treatments and the pressing need for more effective solutions to halt the disease's progression. A case in point is BRIM Biotechnology Inc., a clinical-stage company based in Taiwan, which secured Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for BRM424, a recombinant human nerve growth factor. This compound stimulates the proliferation and differentiation of corneal limbal stem cells, facilitating the regeneration and restoration of corneal health in patients afflicted with neurotrophic keratitis.

In July 2022, Regenerx Biopharmaceuticals Inc., a US-based clinical-stage drug development company, along with its joint venture and licensee partner, HLB Therapeutics Co. Ltd., a biotechnology company based in South Korea, entered into a letter of intent with a global ophthalmology contract research organization (CRO). This collaboration is focused on conducting Phase III clinical trials in the US and Europe for the treatment of neurotrophic keratitis (NK). RGN-259, a sterile and preservative-free eye drop formulation containing thymosin beta 4, a naturally occurring peptide that facilitates tissue repair and healing, is the subject of evaluation. The Phase III clinical trial will assess the efficacy and safety of RGN-259 ophthalmic solution in promoting the healing of persistent epithelial defects in patients with Stages 2 and 3 neurotrophic keratopathies.clinical-stage drug development company.

Major players in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Grand Pharma Co. Ltd., Walgreen Co., Pfizer Inc., Johnson and Johnson, Bayer AG, Novartis AG, Abbott Laboratories, Gilead Biosciences Inc., Merck and Co. Inc., Allergan Inc., Alcon Inc., Bausch Health Companies Inc., Bausch & Lomb Inc., CooperVision Inc., Rohto Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Zhejiang Conba Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Limited, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc., Laboratoires Thea SAS, Leadiant Biosciences Inc., ReGenTree LLC, Contacare Opthalmic Private Limited, Neuroptika Inc., Surgitech Innovation Private Limited .

North America was the largest region in the neurotrophic keratitis treatment market in 2023. The regions covered in neurotrophic keratitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurotrophic keratitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurotrophic keratitis treatment market consists of revenues earned by entities by providing services such as ophthalmic evaluation, prescription of medications, corneal neurotization, customized treatment plans, counseling and support, tarsorrhaphy and antibiotic medication supplements. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurotrophic keratitis market also includes sales of artificial tears, recombinant human nerve growth factor eye drops, antibiotics and bandage contact lenses. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Neurotrophic Keratitis Treatment Market Characteristics

3. Neurotrophic Keratitis Treatment Market Trends And Strategies

4. Neurotrophic Keratitis Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Neurotrophic Keratitis Treatment Market Size and Growth

  • 5.1. Global Neurotrophic Keratitis Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Neurotrophic Keratitis Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Neurotrophic Keratitis Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Neurotrophic Keratitis Treatment Market Segmentation

  • 6.1. Global Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Topical Antibiotics
  • Recombinant Human Nerve Growth Factor (rhNGF)
  • Amniotic Membrane Transplantation
  • Keratoplasty
  • Other Treatments
  • 6.2. Global Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Topical
  • Other Routes of Administration
  • 6.3. Global Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Stage I
  • Stage II
  • Stage III
  • 6.4. Global Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End-Users

7. Neurotrophic Keratitis Treatment Market Regional And Country Analysis

  • 7.1. Global Neurotrophic Keratitis Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Neurotrophic Keratitis Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Neurotrophic Keratitis Treatment Market

  • 8.1. Asia-Pacific Neurotrophic Keratitis Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Neurotrophic Keratitis Treatment Market

  • 9.1. China Neurotrophic Keratitis Treatment Market Overview
  • 9.2. China Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Neurotrophic Keratitis Treatment Market

  • 10.1. India Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Neurotrophic Keratitis Treatment Market

  • 11.1. Japan Neurotrophic Keratitis Treatment Market Overview
  • 11.2. Japan Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Neurotrophic Keratitis Treatment Market

  • 12.1. Australia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Neurotrophic Keratitis Treatment Market

  • 13.1. Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Neurotrophic Keratitis Treatment Market

  • 14.1. South Korea Neurotrophic Keratitis Treatment Market Overview
  • 14.2. South Korea Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Neurotrophic Keratitis Treatment Market

  • 15.1. Western Europe Neurotrophic Keratitis Treatment Market Overview
  • 15.2. Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Neurotrophic Keratitis Treatment Market

  • 16.1. UK Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Neurotrophic Keratitis Treatment Market

  • 17.1. Germany Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Neurotrophic Keratitis Treatment Market

  • 18.1. France Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Neurotrophic Keratitis Treatment Market

  • 19.1. Italy Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Neurotrophic Keratitis Treatment Market

  • 20.1. Spain Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Neurotrophic Keratitis Treatment Market

  • 21.1. Eastern Europe Neurotrophic Keratitis Treatment Market Overview
  • 21.2. Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Neurotrophic Keratitis Treatment Market

  • 22.1. Russia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Neurotrophic Keratitis Treatment Market

  • 23.1. North America Neurotrophic Keratitis Treatment Market Overview
  • 23.2. North America Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Neurotrophic Keratitis Treatment Market

  • 24.1. USA Neurotrophic Keratitis Treatment Market Overview
  • 24.2. USA Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Neurotrophic Keratitis Treatment Market

  • 25.1. Canada Neurotrophic Keratitis Treatment Market Overview
  • 25.2. Canada Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Neurotrophic Keratitis Treatment Market

  • 26.1. South America Neurotrophic Keratitis Treatment Market Overview
  • 26.2. South America Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Neurotrophic Keratitis Treatment Market

  • 27.1. Brazil Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Neurotrophic Keratitis Treatment Market

  • 28.1. Middle East Neurotrophic Keratitis Treatment Market Overview
  • 28.2. Middle East Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Neurotrophic Keratitis Treatment Market

  • 29.1. Africa Neurotrophic Keratitis Treatment Market Overview
  • 29.2. Africa Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Neurotrophic Keratitis Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Neurotrophic Keratitis Treatment Market Competitive Landscape
  • 30.2. Neurotrophic Keratitis Treatment Market Company Profiles
    • 30.2.1. Eyevance Pharmaceuticals LLC
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Grand Pharma Co. Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Walgreen Co.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Pfizer Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Johnson and Johnson
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Neurotrophic Keratitis Treatment Market Other Major And Innovative Companies

  • 31.1. Bayer AG
  • 31.2. Novartis AG
  • 31.3. Abbott Laboratories
  • 31.4. Gilead Biosciences Inc.
  • 31.5. Merck and Co. Inc.
  • 31.6. Allergan Inc.
  • 31.7. Alcon Inc.
  • 31.8. Bausch Health Companies Inc.
  • 31.9. Bausch & Lomb Inc.
  • 31.10. CooperVision Inc.
  • 31.11. Rohto Pharmaceutical Co. Ltd.
  • 31.12. Santen Pharmaceutical Co. Ltd.
  • 31.13. Zhejiang Conba Pharmaceutical Co. Ltd.
  • 31.14. Glenmark Pharmaceuticals Limited
  • 31.15. Dompe farmaceutici S.p.A

32. Global Neurotrophic Keratitis Treatment Market Competitive Benchmarking

33. Global Neurotrophic Keratitis Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Neurotrophic Keratitis Treatment Market

35. Neurotrophic Keratitis Treatment Market Future Outlook and Potential Analysis

  • 35.1 Neurotrophic Keratitis Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Neurotrophic Keratitis Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Neurotrophic Keratitis Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer